631 filings
Page 24 of 32
DEFA14A
NBSE
NeuBase Therapeutics Inc
28 Mar 14
Additional proxy soliciting materials
12:00am
SC 13G
NBSE
NeuBase Therapeutics Inc
24 Mar 14
Ohr Pharmaceutical Inc
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
14 Mar 14
Entry into a Material Definitive Agreement
12:00am
DEF 14A
NBSE
NeuBase Therapeutics Inc
7 Mar 14
Definitive proxy
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
3 Mar 14
Ohr Pharmaceutical and Cold Spring Harbor Laboratory Announce Joint Venture to Develop Trodusquemine and Related Analogs
12:00am
SC 13G/A
Alpert Charles
21 Feb 14
Beneficial ownership report (amended)
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
20 Feb 14
Positive Case Report on Ohr Pharmaceutical’s Squalamine Presented at the 37th Annual Macula Society Meeting
12:00am
SC 13G
Hirschman Orin
14 Feb 14
Beneficial ownership report
12:00am
10-Q
2014 Q1
NBSE
NeuBase Therapeutics Inc
Quarterly report
14 Feb 14
12:00am
SC 13G/A
NBSE
NeuBase Therapeutics Inc
14 Feb 14
Beneficial ownership report (amended)
12:00am
SC 13G
NBSE
NeuBase Therapeutics Inc
14 Feb 14
Ohr Pharmaceutical Inc
12:00am
SC 13G
Alpert Charles
13 Feb 14
Beneficial ownership report
12:00am
SC 13G
GCK Holdings Corp.
13 Feb 14
Beneficial ownership report
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
11 Feb 14
Regulation FD Disclosure
12:00am
EFFECT
NBSE
NeuBase Therapeutics Inc
31 Jan 14
Notice of effectiveness
12:00am
S-3/A
NBSE
NeuBase Therapeutics Inc
Shelf registration (amended)
31 Jan 14
12:00am
CORRESP
NBSE
NeuBase Therapeutics Inc
29 Jan 14
Correspondence with SEC
12:00am
CORRESP
NBSE
NeuBase Therapeutics Inc
29 Jan 14
Correspondence with SEC
12:00am
S-3/A
NBSE
NeuBase Therapeutics Inc
29 Jan 14
Shelf registration (amended)
12:00am
CORRESP
NBSE
NeuBase Therapeutics Inc
29 Jan 14
Correspondence with SEC
12:00am